Berenberg announced on Thursday that it had lowered its price target for Eurofins Scientific from €105 to €65, but reiterated its buy recommendation on the stock.

In a research note, the research firm points out that the testing, inspection and certification sector has been heavily penalized on the stock market this year, but that Eurofins has suffered the most severe penalty.

With the end of the Covid epidemic, investors' attention is once again focused on core business, margin trends and cash flow optimization," he points out in his study.

From this point of view, the analyst believes that the market's interest in the bio-analysis specialist is 'undervalued', and adds that the medium-term objectives set by the company are perfectly attainable.

In his opinion, the stock will revalue once the concerns surrounding the financing of the group's growth have dissipated somewhat.

Copyright (c) 2023 CercleFinance.com. All rights reserved.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.